Advertisement
UK markets open in 3 hours 24 minutes

  • NIKKEI 225

    36,818.81
    -1,260.89 (-3.31%)
     

  • HANG SENG

    16,083.78
    -302.09 (-1.84%)
     

  • CRUDE OIL

    85.01
    +2.28 (+2.76%)
     

  • GOLD FUTURES

    2,403.10
    +5.10 (+0.21%)
     

  • DOW

    37,775.38
    +22.07 (+0.06%)
     

  • Bitcoin GBP

    49,788.25
    -182.00 (-0.36%)
     

  • CMC Crypto 200

    1,273.55
    +388.02 (+42.02%)
     

  • NASDAQ Composite

    15,601.50
    -81.87 (-0.52%)
     

  • UK FTSE All Share

    4,290.02
    +17.00 (+0.40%)
     
Money:

Best mortgage deals of the week

As possibility of multiple interest rate cuts dwindle here's what banks and building societies are offering

Atara (ATRA) Looks Good: Stock Adds 5.1% in Session

Zacks Equity Research
·2-min read

Atara Biotherapeutics, Inc. ATRA was a big mover last session, as the company saw its shares rise more than 5% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This breaks the recent trend of the company, as the stock is now trading above the volatile price range of $11.92 to $14.83 in the past one-month time frame.

The move came after the company reported encouraging results regarding the Phase 1a Study of ATA188 for the treatment of progressive forms of multiple sclerosis.
 
The company has seen no changes when it comes to estimate revision over the past few weeks, while the Zacks Consensus Estimate for the current quarter has also remained unchanged. The recent price action is encouraging though, so make sure to keep a close watch on this firm in the near future.

Atara Biotherapeutics, Inc. Price

Atara Biotherapeutics, Inc. Price
Atara Biotherapeutics, Inc. Price

Atara Biotherapeutics, Inc. price | Atara Biotherapeutics, Inc. Quote

ADVERTISEMENT

Atara currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.

Investors interested in the Medical - Biomedical and Genetics industry may consider Emergent BioSolutions Inc. EBS, which has a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Breakout Biotech Stocks with Triple-Digit Profit Potential

The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.

Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.

See these 7 breakthrough stocks now>>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Emergent Biosolutions Inc. (EBS) : Free Stock Analysis Report
 
Atara Biotherapeutics, Inc. (ATRA) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research